LTRN

Lantern Pharma Inc. (LTRN) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Lantern Pharma Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary RADR® artificial intelligence platform to identify drug candidates and patient populations for targeted oncology therapies. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 5, 2024, there were 10,764,725 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the six months ended June 30, 2024, increased by approximately $1.79 million (21%) compared to the same period in 2023, driven primarily by higher R&D expenses.
• R&D Expenses: Increased by approximately $2.03 million (33%) year-over-year for the six-month period. This was due to increased research study costs ($2.27M), payroll ($0.41M), and consulting ($0.26M), partially offset by a decrease in manufacturing expenses ($0.91M).
• G&A Expenses: Decreased by approximately $0.36 million (11%) year-over-year for the six-month period, attributed to reductions in payroll, insurance, and office expenses, offset by higher legal and professional fees.
• Interest Income: Increased by approximately $0.14 million (55%) for the six-month period due to higher yields on cash and marketable securities.
• Cash Position: Cash and cash equivalents decreased from $21.94 million at year-end 2023 to $12.98 million at June 30, 2024, reflecting operating cash burn of $8.26 million for the six-month period.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities (~$33.3 million) are sufficient to fund operations for at least 12 months from the filing date. The company plans to explore periodic capital raises and grant funding.
• Clinical Pipeline:
  • LP-300 (Tavocept): Advancing in the Harmonic™ Phase 2 trial for never-smokers with advanced non-small cell lung cancer (NSCLC).
  • LP-184 (STAR-001): Advancing in Phase 1 for solid tumors and CNS cancers (via subsidiary Starlight Therapeutics).
  • LP-284: Advancing in Phase 1 for hematological cancers.
  • ADC Program: Preclinical optimization of antibody-drug conjugates using cryptophycin payloads.
• Risks: The company has no revenue and expects to incur significant losses for the foreseeable future. Risks include the failure of clinical trials, inability to secure additional funding, regulatory hurdles, and the inherent uncertainties of AI-driven drug discovery. Substantially all cash balances exceed FDIC insurance limits.
• Unusual Items: The company recognized unrealized losses on marketable securities of approximately $0.49 million as of June 30, 2024, though management does not believe these represent credit losses.

Investor Verification Checklist

• Verify the progress and enrollment rates of the Harmonic™ Phase 2 trial for LP-300, as this is the most advanced clinical asset.
• Confirm the timeline for the amendment to the Fortrea work order regarding the LP-300 trial, expected in Q3 2024, to assess potential cost impacts.
• Monitor the cash burn rate relative to the $33.3 million liquidity position to determine the runway for future capital raises.
• Review the status of the Actuate Therapeutics collaboration extension discussions, as this represents a potential non-dilutive revenue or partnership opportunity.
• Assess the valuation and unrealized losses on the marketable securities portfolio ($20.3 million) to understand potential volatility in the balance sheet.